B2M and cancer: Epigenetic modifying agents (EMAs), including histone modifiers and DNA methyltransferase inhibitors, can influence tumor immunogenicity by modulating the expression of cancer-associated antigens (e.g., cancer-testis antigens), cytokines, and key components of the antigen processing and presentation machinery, such as TAP, HLA class I molecules, and β2M (93).